Article (Scientific journals)
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Gevaert, Philippe; Van Bruaene, Nicholas; Cattaert, Tom et al.
2011In Journal of Allergy and Clinical Immunology, 128 (5), p. 989-995.e8
Peer Reviewed verified by ORBi
 

Files


Full Text
Gevaert2011.pdf
Author postprint (775.45 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] BACKGROUND: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. OBJECTIVE: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. METHODS: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blind fashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. RESULTS: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. CONCLUSION: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
Disciplines :
Otolaryngology
Author, co-author :
Gevaert, Philippe
Van Bruaene, Nicholas
Cattaert, Tom ;  Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Steen, Kristel  ;  Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Zele, Thibaut
Acke, Frederic
De Ruyck, Natalie
Blomme, Katrien
Sousa, Ana R
Marshall, Richard P
Bachert, Claus
Language :
English
Title :
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Publication date :
2011
Journal title :
Journal of Allergy and Clinical Immunology
ISSN :
0091-6749
eISSN :
1097-6825
Publisher :
Mosby, St Louis, United States - Missouri
Volume :
128
Issue :
5
Pages :
989-995.e8
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright A(c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Available on ORBi :
since 01 November 2011

Statistics


Number of views
86 (8 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
 
510
Scopus citations®
without self-citations
449
OpenCitations
 
459

Bibliography


Similar publications



Contact ORBi